{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:40Z","timestamp":1792521460253,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s41030-024-00275-x","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T17:01:45Z","timestamp":1728579705000},"page":"439-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Survival Outcomes in US Medicare Patients with Non-Cystic Fibrosis Bronchiectasis by Rate of Baseline Exacerbations"],"prefix":"10.1007","volume":"10","author":[{"given":"Joseph","family":"Feliciano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lewing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitreyee","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lauterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Fucile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tkacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"275_CR1","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","volume":"197","author":"JD Chalmers","year":"2018","unstructured":"Chalmers JD, Aliberti S, Filonenko A, et al. Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis. Am J Respir Crit Care Med. 2018;197:1410\u201320.","journal-title":"Am J Respir Crit Care Med"},{"key":"275_CR2","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:1700629.","journal-title":"Eur Respir J"},{"key":"275_CR3","doi-asserted-by":"publisher","first-page":"1700051","DOI":"10.1183\/13993003.00051-2017","volume":"49","author":"AT Hill","year":"2017","unstructured":"Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49:1700051.","journal-title":"Eur Respir J"},{"key":"275_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1479972317709649","volume":"14","author":"D Weycker","year":"2017","unstructured":"Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis. 2017;14:377\u201384.","journal-title":"Chron Respir Dis"},{"key":"275_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107217","volume":"211","author":"PA Flume","year":"2023","unstructured":"Flume PA, Basavaraj A, Garcia B, et al. Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis. Respir Med. 2023;211: 107217.","journal-title":"Respir Med"},{"key":"275_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.cpm.0000171422.98696.ed","volume":"12","author":"D Weycker","year":"2005","unstructured":"Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205\u20139.","journal-title":"Clin Pulm Med"},{"key":"275_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.rmed.2013.12.015","volume":"108","author":"PC Goeminne","year":"2014","unstructured":"Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med. 2014;108:287\u201396.","journal-title":"Respir Med"},{"key":"275_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032537","volume":"101","author":"SP Mateus","year":"2022","unstructured":"Mateus SP, Ribeiro-Alves M, Salles REB, et al. Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up. Medicine (Baltimore). 2022;101: e32537.","journal-title":"Medicine (Baltimore)"},{"key":"275_CR9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.17219\/acem\/144200","volume":"30","author":"A Nowinski","year":"2021","unstructured":"Nowinski A, Stachyra K, Szybinska M, Bednarek M, Plywaczewski R, Sliwinski P. The influence of comorbidities on mortality in bronchiectasis: a prospective, observational study. Adv Clin Exp Med. 2021;30:1315\u201321.","journal-title":"Adv Clin Exp Med"},{"key":"275_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12931-019-1243-3","volume":"20","author":"S Sin","year":"2019","unstructured":"Sin S, Yun SY, Kim JM, et al. Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis. Respir Res. 2019;20:271.","journal-title":"Respir Res"},{"key":"275_CR11","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1038\/s41598-021-86407-8","volume":"11","author":"H Choi","year":"2021","unstructured":"Choi H, Yang B, Kim YJ, et al. Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities. Sci Rep. 2021;11:7126.","journal-title":"Sci Rep"},{"key":"275_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12890-019-0818-6","volume":"19","author":"PC Goeminne","year":"2019","unstructured":"Goeminne PC, Hernandez F, Diel R, et al. The economic burden of bronchiectasis\u2014known and unknown: a systematic review. BMC Pulm Med. 2019;19:54.","journal-title":"BMC Pulm Med"},{"key":"275_CR13","first-page":"A2148","volume":"187","author":"VN Joish","year":"2013","unstructured":"Joish VN, Spilsbury-Cantalupo M, Kamalakar R, Operschall E, Luong B. Direct medical costs associated with exacerbations related to non-cystic fibrosis bronchiectasis among elderly. Am J Respir Crit Care Med. 2013;187:A2148.","journal-title":"Am J Respir Crit Care Med"},{"key":"275_CR14","doi-asserted-by":"publisher","first-page":"A4933","DOI":"10.1016\/j.chest.2023.07.3198","volume":"164","author":"J Feliciano","year":"2023","unstructured":"Feliciano J, Tkacz J, Lewing B, et al. Incremental health care utilization and costs associated with bronchiectasis in a Medicare population. Chest. 2023;164:A4933\u20134.","journal-title":"Chest"},{"key":"275_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21037\/atm-22-3437","volume":"11","author":"H Choi","year":"2023","unstructured":"Choi H, Chalmers JD. Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention. Ann Transl Med. 2023;11:25.","journal-title":"Ann Transl Med"},{"key":"275_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","volume":"189","author":"JD Chalmers","year":"2014","unstructured":"Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189:576\u201385.","journal-title":"Am J Respir Crit Care Med"},{"key":"275_CR17","doi-asserted-by":"publisher","first-page":"00081","DOI":"10.1183\/23120541.00081-2015","volume":"2","author":"JD Chalmers","year":"2016","unstructured":"Chalmers JD, Aliberti S, Polverino E, et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Res. 2016;2:00081\u20132015.","journal-title":"ERJ Open Res"},{"key":"275_CR18","doi-asserted-by":"publisher","first-page":"00296","DOI":"10.1183\/23120541.00296-2022","volume":"9","author":"I Marsland","year":"2023","unstructured":"Marsland I, Sobala R, De Soyza A, Witham M. Multimorbidity in bronchiectasis: a systematic scoping review. ERJ Open Res. 2023;9:00296\u20132022.","journal-title":"ERJ Open Res"},{"key":"275_CR19","doi-asserted-by":"publisher","first-page":"A116","DOI":"10.1016\/j.jval.2016.03.458","volume":"19","author":"RL Germino","year":"2016","unstructured":"Germino RL. Resource utilization associated with non-cystic fibrosis bronchiectasis patients who are being treated for exacerbations. Value in Health. 2016;19:A116.","journal-title":"Value in Health"},{"key":"275_CR20","first-page":"967","volume":"30","author":"J Tkacz","year":"2024","unstructured":"Tkacz J, Lewing B, Feliciano J, et al. Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis. J Manag Care Spec Pharm. 2024;30:967\u201377.","journal-title":"J Manag Care Spec Pharm"},{"key":"275_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1183\/13993003.01033-2015","volume":"47","author":"JK Quint","year":"2016","unstructured":"Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47:186\u201393.","journal-title":"Eur Respir J"},{"key":"275_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/CLEP.S105613","volume":"9","author":"KE Mues","year":"2017","unstructured":"Mues KE, Liede A, Liu J, et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267\u201377.","journal-title":"Clin Epidemiol"},{"key":"275_CR23","doi-asserted-by":"publisher","first-page":"147997311983996","DOI":"10.1177\/1479973119839961","volume":"16","author":"FD Seifer","year":"2019","unstructured":"Seifer FD, Hansen G, Weycker D. Health-care utilization and expenditures among patients with comorbid bronchiectasis and chronic obstructive pulmonary disease in US clinical practice. Chron Respir Dis. 2019;16:1479973119839961.","journal-title":"Chron Respir Dis"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-024-00275-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:38:04Z","timestamp":1732034284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-024-00275-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["275"],"URL":"https:\/\/doi.org\/10.1007\/s41030-024-00275-x","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joseph Tkacz and Benjamin Lewing are employees of Inovalon, a paid consultant for Insmed Incorporated. Joseph Feliciano, Maitreyee Mohanty, Melanie Lauterio, and Sebastian Fucile are employees and shareholders of Insmed Incorporated. Alan F Barker has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective, observational study was verified as exempt from an ethical approval by Solutions IRB according to the Code of Federal Regulations under 45 CFR 46 section 101(b)(4) as the study used previously existing, anonymized, and deidentified patient data. For this type of study, informed consent is waived\/not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Medical writing support was provided by Rosie Morley PhD, of Envision Pharma Group, and funded by Insmed Incorporated.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing\/Editorial Assistance"}}]}}